The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.

The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.

Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.

Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.

After Niagara the company faces three pivotal catalysts; none is a slam-dunk.

Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.

A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.